Bayer Aktiengesellschaft

Matthias Schramm

Rainer Gross

Gerhard Franckowiak

Martin Bechem

Gunter Thomas

Siegfried Goldmann

Jurgen Stoltefuss

Michael Kayser

Siegbert Hebisch

Gunther Thomas

Elisabeth Perzborn

Horst Boshagen

Horst Meyer

Ulrich Niewohner

Fred R Heiker

Friedrich Bossert

Erwin Bischoff

Friedel Seuter

Eckhard Schwenner

Helmuth Schutz

Albrecht Marhold

Johannes-Peter Stasch

Stanislav Kazda

Claudia Hirth

Andreas Knorr

Egbert Wehinger

Ulrich E Muller

Ulrich Rosentreter

Rolf Grosser

Wolfgang Hartwig

Joachim Hutter

Robertson Towart

Howard-Paul Rounding

Gerhard Schluter

Bernd Pelster

Gu/ Nter Thomas

Ulrich Bartke

Klaus Gorlitzer

Ulrich Posanski

Siegfried Hebisch

Bernhard Beckermann

9-Substituted 2-(2-n-alkoxyphenyl)purin-6-ones are prepared by cyclizing correspondingly substituted imidazoles and derivatizing the purines thus obtained. The 9-substituted .sup.2 -(2-n-alkoxyphenyl)purin-6-ones can be employed as active compounds in medicaments, in particular in medicarnents for treatment of inflammations, thromboembolic diseases and cardiovascular diseases.

9-substituted 2-(2-n-alkoxyphenyl)-purin-6-ones

2,9-Disubstituted purin-6-ones are prepared by acylating correspondingly substituted aminoimidazoles in a first step and then cyclizing the product to the purine. The new 2,9-disubstituted purin-6-ones can be employed as active compounds in medicaments, in particular for the treatment of inflammations, thromboembolic and cardiovascular diseases and diseases of the urogenital system.

2,9-disubstituted purin-6-ones

2,8-Disubstituted quinazolinones are prepared by first subjecting the quinazolinone basic skeleton to condensation by customary reactions and then introducing the desired substituents into the 8-position. The compounds are suitable as active compounds in medicaments, in particular for the treatment of inflammations, thromboembolic diseases and cardiovascular diseases.

2,8-disubstituted quinazolinones

The present invention relates to the use of 3-formyl-1,4-dihydropyridine derivatives as medicaments for the control of cardiovascular diseases, in particular of pathologically changed blood pressure and of cardiac insufficiency, new compounds and a process for their preparation.

Certain 3-formyl-1, 4-dihydropyridines and their pharmaceutical

Circulation-active dihydropyridines of the formula ##STR1## in which R.sup.1 is H, CN, NO.sub.2 or --COOR.sup.7,

Circulation-active dioxyalkylenearyl-dihydropyridines

Indolesulphonamide-substituted dihydropyridines can be prepared by reaction of dihydropyridinecarboxylic acids with hydroxy-substituted indolesulphonamides, or by reaction of amino- or hydroxy-substituted dihydropyridines with indolesulphonamidecarboxylic acids. The indolesulphonamide-substituted dihydropyridines can be employed as active substances in medicaments for the treatment of cardiac, circulatory and thromboedabolic disorders.

Indolesulphonamide-substituted dihydropyridines

4 Aminoaryldihydropyridines of the formula ##STR1## in which R.sup.1 is hydrogen or an organic radical, preferably methyl or ethyl,

Circulation active 4-aminoaryldihydropryidine lactones

Cardioactive dihydropyridines of the formula ##STR1## in which Y is ##STR2## A is H or CH.sub.3, B is --NH, --NH--CO--, --NH--CS--, --NH--COO--, --NH--SO.sub.2 --or --NH--CO--NH-- or --NH--CS--NH--, and

1,4-dihydropyridine-threonine derivatives with cardiovascular activity

Hypertension and cardiac insufficiency can be controlled by 4-nitrophenyl-dihydropyridine amides of the formula ##STR1## in which X can be ethylene or the like,

Pharmaceutically active basic nitro-phenyl-dihydropyridine amides

1,4-dihydropyridine-threonine compounds with cardiovascular activity

Circulation active dihydropyridine amides of the formula ##STR1## in which R.sup.6 represents a group of the formula --O--(CH.sub.2).sub.n --R.sup.10, --S--(CH.sub.2).sub.n --R.sup.10 --O--SO.sub.2 --(CH.sub.2).sub.n R.sup.10 or --O--CO--(CH.sub.2).sub.n --R.sup.10 in which

Circulation-active basic 4-aryl-DHP amides

Circulation-active fluoromethoxyphenyldihydropyridines of the formula ##STR1## in which X stands for hydrogen or fluorine and

Circulation-active fluoromethoxyphenyl dihydropyridine compounds

A benzylaminoaryl-dihydropyridinelactone compound of the formula (I) ##STR1## in which R.sup.1 represents hydrogen, halogen, cyano, nitro, C.sub.6 -C.sub.12 -aryl, C.sub.1 -C.sub.8 -alkyl, C.sub.1 -C.sub.8 -alkoxy, C.sub.1 -C.sub.6 -alkylthio, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, difluoromethoxy, di-C.sub.1 -C.sub.5 -alkylamino, C.sub.1 -C.sub.6 -alkoxycarboxyl or C.sub.1 -C.sub.6 -alkylsulphonyl,

Benzylaminoaryl-dihydropyridinelactones and their use in medicaments

Novel circulation-active cyclohexenecarboxylates of the formula ##STR1## in which R.sup.1 is an organic radical,

Circulation-active cyclohexenecarboxylates

Circulation active nitrodihydropyridines of the formula ##STR1## in which R represents aryl which has 6 to 12 carbon atoms and can be substituted up to 4 times, identically or differently, by halogen, nitro, cyano, alkyl, alkoxy, alkylthio, in each case having up to 6 carbon atoms, trifluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio, difluoromethylenedioxy, trifluoroethylenedioxy or tetrafluoroethylenedioxy or by benzyl, benzyloxy or benzylthio, each of which is optionally substituted by halogen, nitro, cyano, trifuoromethyl, alkyl having up to 4 carbon atoms or alkoxy having up to 4 carbon atoms, or represents a heterocycle which is optionally substituted by halogen, phenyl or alkyl having up to 4 carbon atoms and is from the group consisting of pyrryl, thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidyl, pyridazinyl, quinolyl, benzoxadiazolyl, chromenyl or thiochromenyl, and

[4-(6-Oxo-1,4,5,6-tetrahydro-3-pyridazinyl) anilino hexyl

Growing community of inventors

Cologne, Germany

Matthias Schramm